Ownership and insider activity for Arrowhead Pharmaceuticals, Inc. (ARWR): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology.
Price
| Price | $59.90 (closing price, October 30, 2026) |
| Market Cap | $8.5B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-18 | OLUKOTUN ADEOYE Y | S-Sale | 2,000 | $174K |
| 2026-08-18 | PERRY MICHAEL S | S-Sale | 11,600 | $1.0M |
| 2026-06-15 | Cohen Matthew Gregory | A-Award | 11,882 | |
| 2026-06-15 | Cohen Matthew Gregory | |||
| 2026-05-12 | Lu Hongbo | S-Sale | 2,970 | $228K |
| 2026-04-22 | Apel Daniel Joseph | S-Sale | 3,208 | $225K |
| 2026-04-22 | Apel Daniel Joseph | S-Sale | 1,157 | $82K |
| 2026-04-22 | Apel Daniel Joseph | S-Sale | 8,730 | $628K |
| 2026-04-23 | Hamilton James C | S-Sale | 10,000 | $750K |
| 2026-03-05 | Hamilton James C | S-Sale | 10,000 | $642K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $85.4M | $24.8M | $30.1M | $221.8M | $143.6M | $184.4M | $108.0M | $110.9M | $102.7M | $226.5M |
| Short-term Investments | 0 | $40.8M | $46.4M | $36.9M | $171.9M | $183.4M | $268.4M | $292.7M | $578.3M | $692.8M |
| Receivables | $75,000 | $67,797 | $327,375 | $661,361 | $845,673 | $10.3M | $1.4M | 0 | 0 | $6.8M |
| Inventory | $1.3M | $867,363 | $1.3M | $3.3M | $4.3M | $4.4M | -$21.6M | 0 | 0 | 0 |
| Total Current Assets | $90.5M | $67.9M | $78.8M | $265.2M | $322.4M | $384.6M | $405.3M | $419.5M | $695.5M | $950.6M |
| Property, Plant & Equipment | $15.4M | $15.5M | $13.9M | $23.2M | $47.0M | $66.0M | $168.6M | $335.6M | $431.3M | $426.4M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $22.2M | $20.5M | $18.8M | $17.1M | $15.4M | $13.7M | $12.0M | $10.3M | $8.6M | $6.9M |
| Total Assets | $128.2M | $104.0M | $111.6M | $349.8M | $522.5M | $710.1M | $691.9M | $765.6M | $1.14B | $1.39B |
| Accounts Payable | $12.2M | $4.1M | $2.8M | $7.6M | $6.8M | $9.5M | $2.9M | $35.9M | $11.4M | $17.7M |
| Short-term Debt | $194,310 | $208,506 | $223,820 | 0 | $1.1M | $2.2M | $2.8M | $10.6M | $6.3M | $40.0M |
| Total Current Liabilities | $25.6M | $18.7M | $12.4M | $97.1M | $40.7M | $146.5M | $138.8M | $105.5M | $103.2M | $195.5M |
| Long-term Debt | $2.5M | $2.3M | $2.1M | 0 | 0 | 0 | 0 | $268.3M | $734.5M | $214.9M |
| Total Liabilities | $33.2M | $23.2M | $16.4M | $105.8M | $60.7M | $301.3M | $273.6M | $478.4M | $948.7M | $881.9M |
| Retained Earnings | -$398.4M | -$432.8M | -$487.3M | -$419.3M | -$503.8M | -$644.7M | -$820.8M | -$1.03B | -$1.63B | -$1.63B |
| Total Equity | $95.6M | $81.4M | $95.8M | $244.6M | $461.8M | $408.8M | $398.5M | $271.3M | $185.4M | $466.1M |
| Total Debt | $2.7M | $2.5M | $2.3M | 0 | $21.1M | $25.5M | $81.6M | $383.5M | $851.9M | $366.3M |
| Net Debt | -$82.6M | -$63.1M | -$74.2M | -$258.7M | -$294.4M | -$342.2M | -$294.8M | -$20.1M | $171.0M | -$553.1M |
| Working Capital | $64.9M | $49.2M | $66.4M | $168.2M | $281.7M | $238.1M | $266.4M | $314.1M | $592.3M | $755.2M |
Financial Health
| Debt / Equity | 1.86 |
| Current Ratio | 5.90 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 2.98 |
Profitability
| Return on Equity | -60.54% |
| Return on Invested Capital | -12.12% |
| Return on Assets | -15.15% |
| Gross Margin | 100.00% |
| Operating Margin | -33.82% |
| Net Margin | -47.79% |
Related companies: ALNY · IONS · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of ARWR: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks